CareDx, Inc. (NASDAQ:CDNA – Get Free Report) Director Michael Goldberg sold 13,800 shares of the business’s stock in a transaction that occurred on Thursday, November 12th. The shares were sold at an average price of $79.15, for a total value of $1,092,270.00. Following the completion of the transaction, the director owned 48,526 shares of the company’s stock, valued at $3,840,832.90. This represents a 22.14% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
CareDx Stock Performance
NASDAQ:CDNA opened at $74.44 on Thursday. The stock has a fifty day moving average price of $67.77 and a 200-day moving average price of $37.51. The company has a market cap of $3.91 billion, a price-to-earnings ratio of 31.15 and a beta of 2.51. CareDx, Inc. has a fifty-two week low of $15.56 and a fifty-two week high of $90.87.
CareDx (NASDAQ:CDNA – Get Free Report) last announced its earnings results on Thursday, October 29th. The company reported $0.70 earnings per share for the quarter, topping analysts’ consensus estimates of $0.25 by $0.45. The firm had revenue of $139.36 million for the quarter, compared to the consensus estimate of $121.96 million. CareDx had a return on equity of 9.74% and a net margin of 25.86%. The company’s revenue was up 39.3% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.03 EPS. Research analysts predict that CareDx, Inc. will post 1.00 EPS for the current fiscal year.
Wall Street Analyst Weigh In
View Our Latest Stock Report on CareDx
Hedge Funds Weigh In On CareDx
Several institutional investors have recently made changes to their positions in the company. BlackRock Inc. acquired a new stake in CareDx in the 2nd quarter valued at about $137,219,000. Bamco Inc. NY acquired a new stake in CareDx in the 2nd quarter worth approximately $55,214,000. Bank of America Corp DE acquired a new position in shares of CareDx in the second quarter valued at $16,297,000. Palo Alto Investors LP acquired a new position in shares of CareDx during the second quarter worth approximately $15,158,295. Finally, Jupiter Topco LLC acquired a new stake in shares of CareDx during the second quarter worth about $9,673,000.
CareDx Company Profile
CareDx, Inc. is a precision medicine company focused on organ transplantation. It develops and provides diagnostic tests and related services to help clinicians assess transplant recipients and monitor their health over time. Its offerings include AlloSure, a donor-derived cell-free DNA test used to help monitor for organ rejection, and AlloMap, a gene-expression test used in heart transplant care. CareDx also provides histocompatibility testing, clinical tools, and services designed to support patients and transplant care teams.
See Also
- Five stocks we like better than CareDx
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for CareDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx and related companies with MarketBeat.com's FREE daily email newsletter.
